Monopar Therapeutics (NASDAQ:MNPR) Director Raymond Anderson Sells 3,142 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the sale, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $113.94 on Friday. The firm has a 50 day simple moving average of $105.56 and a 200-day simple moving average of $74.74. The firm has a market cap of $764.54 million, a PE ratio of -52.51 and a beta of 1.47. Monopar Therapeutics Inc. has a 1-year low of $32.77 and a 1-year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, sell-side analysts expect that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MNPR has been the topic of several analyst reports. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research report on Tuesday, June 2nd. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $109.00 to $119.00 in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $130.00 price target on shares of Monopar Therapeutics in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.67.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets increased its holdings in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics during the 4th quarter worth $65,000. JPMorgan Chase & Co. increased its holdings in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth $80,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.